Aachen und Merck Serono GmbH

Darmstadt, Germany

Aachen und Merck Serono GmbH

Darmstadt, Germany
SEARCH FILTERS
Time filter
Source Type

Storz E.,Vfa Die Forschenden Pharma Unternehmen | Franzen W.-H.,Takeda Pharma GmbH | Fritsch D.,Aachen und Merck Serono GmbH
Pharmazeutische Industrie | Year: 2011

Extensive proposals for strengthening pharmacovigilance in Europe were presented by the European Commission in December 2008. After two years of consultation these proposals were passed and the final versions of the Regulation and the Directive were published on December 31, 2010. The requirements of the Directive now must be implemented by the Member States by July 2012. Extensive changes can be expected in the areas of periodic safety update reports, publication of documents and information via web portals, reporting rules and performance of post-authorization safety and efficacy studies. Many of these measures will improve transparency and will lead to simplification of pharmacovigilance. Others are seen more critically by the pharmaceutical industry. This article will evaluate some of the most important changes from the pharmaceutical industry viewpoint. © ECV Editio Cantor Verlag.

Loading Aachen und Merck Serono GmbH collaborators
Loading Aachen und Merck Serono GmbH collaborators